Hepatic Dysfunction in a Child Post Bone Marrow Transplantation

Sood, Vikrant; Chawla, Juhi; Lal, Bikrant Bihari; Khanna, Rajeev; Bihari, Chhagan; Alam, Seema

doi:10.1016/j.jceh.2018.04.014

Cited by 1 publication

(2 citation statements)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Long term, there is also an increased risk for developing cirrhosis, hepatic dysfunction, and hepatocellular carcinoma at an accelerated rate, as early as 7 months post-transplant. [10][11][12][13][14][15] As a result of the limited number of HCV-positive pediatric patients with beta-thalassemia undergoing a HSCT, there is relatively minimal information on the appropriate clinical course of management. In addition, the development of DAAs for treatment of HCV has provided a highly efficacious treatment for eradicating the infection.…”

Section: Discussionmentioning

confidence: 99%

“…HCV at the time of transplant is associated with increased risk to develop GvHD compared with non‐HCV–infected HSCT recipients . Long term, there is also an increased risk for developing cirrhosis, hepatic dysfunction, and hepatocellular carcinoma at an accelerated rate, as early as 7 months post‐transplant . As a result of the limited number of HCV‐positive pediatric patients with beta‐thalassemia undergoing a HSCT, there is relatively minimal information on the appropriate clinical course of management.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of allogeneic hematopoietic stem cell transplantation in beta‐thalassemia patients with chronic hepatitis C infections treated at a pediatric center

Ramgopal

Lauko

Rotz

et al. 2019

Pediatric Transplantation

View full text Add to dashboard Cite

The outcome of allogeneic HCT in patients previously infected with HCV is a widely debated topic and rarely reported in the pediatric and young adult age group given the small population of affected patients. New medications directly targeting HCV have induced virologic cures for over 90% of patients, and their use in the pretransplant setting may improve outcomes for patients infected with HCV. We describe two patients with transfusion‐dependent beta‐thalassemia major who underwent matched sibling donor bone marrow transplantation, one with a myeloablative regimen and one with a reduced‐intensity conditioning regimen. Allogeneic HCT appears feasible in patients with HCV infection that clear viremia prior to conditioning therapy and with a reduced‐intensity conditioning regimen. Further investigation is warranted to better define transplant risks in this population.

show abstract